Nuvo Pharmaceuticals Inc (MRV)

0.65
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.65/0.70
  • Day's Range:
    0.65 - 0.66

MRV Overview

Prev. Close
0.66
Day's Range
0.65-0.66
Revenue
72.42M
Open
0.66
52 wk Range
0.5-1.59
EPS
1.33
Volume
0
Market Cap
7.4M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
5,590
P/E Ratio
2.30
Beta
1.4
1-Year Change
-58.06%
Shares Outstanding
11,388,282
Next Earnings Date
Mar 01, 2023
What is your sentiment on Nuvo Pharma?
or
Market is currently closed. Voting is open during market hours.

Nuvo Pharmaceuticals Inc News

Nuvo Pharmaceuticals Inc Analysis

Nuvo Pharmaceuticals Inc Company Profile

Nuvo Pharmaceuticals Inc Company Profile

Employees
108
Market
Canada
  • Type:Equity
  • Market:Canada
  • ISIN:CA67092F1045
  • CUSIP:67092F104

Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA and RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was incorporated in 1983 and is headquartered in Mississauga, Canada.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell